HER2 양성 전이성 유방암 환자에서 trastuzumab-deruxtecan 관련 사회경제적 편익 분석

• Published in: Yaghag-hoi-ji Vol. 67; no. 4; pp. 252 - 260
• Main Authors: 최아형, 고화연, 홍빈, 배지환, 오인선, 박선경, 박연희, 신주영
• Format: Journal Article
• Language: Korean
• Published: The Pharmaceutical Society Of Korea 31.08.2023; 대한약학회
• Subjects: 약학; HER2 positive metastatic breast cancer; Trastuzumab-deruxtecan; Socioeconomic benefits
• ISSN: 0377-9556; 2383-9457
• DOI: 10.17480/psk.2023.67.4.252

In the recent DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd) has shown significantly prolongedprogression free survival (PFS) compared with trastuzumab emtansine (T-DM1) among human epidermal growth factor2-positive metastatic breast cancer (HER2+ MBC) patients. While there is clear evidence of the clinical benefits of T-DXd,evidence on societal effects that go beyond these clinical benefits is yet to be explored. Thus, we estimated thesocioeconomic benefits of T-DXd compared to T-DM1 among HER2+ MBC patients. We first calculated the incrementalhealth benefits that T-DXd generates compared to T-DM1 in terms of prolonged PFS. We then translated the incrementalPFS into the time spent on paid work and unpaid work hours. Lastly, the overall societal impact of T-DXd was yieldedby aggregating the potential gross domestic products that can be generated from both paid and unpaid work hours. Weidentified 2,212 patients who are eligible for the analyses. Overall, the prolonged PFS of T-DXd resulted in asocioeconomic benefit of approximately 260 billion KRW, which corresponded to 110 million KRW per patient. Inconclusion, we observed considerable socioeconomic benefits that come along with the use of the novel drug, T-DXd,which will be helpful for healthcare policymakers in decision-making. KCI Citation Count: 0